Preclinical and clinical pharmacology of antisense oligonucleotides.
Antisense oligonucleotides are short (typically 15-20 bases in length pieces of synthetically manufactured, chemically modified DNA or RNA. They are designed to interact by Watson-Crick base pairing with mRNA transcripts encoding proteins of interest, and by virtue of this interaction inhibit the expression of the protein encoded in the mRNA. Since their first proposed use in 1978, antisense oligonucleotides have become come widely used as tools to modulate gene expression in tissue culture. The great specificity that these compounds exhibited in vitro has also led them to be viewed as potentially therapeutically useful. This interest has resulted in the progression of (to date) a dozen compounds into human clinical trials for a variety of indications ranging from cancer to inflammatory diseases. Here, we will review some of the progress that has been made with antisense pharmacology, both in vitro and in vivo, as well as describe the current status of this class of compound in clinical trials.
Marcusson
E G
EG
Immusol Inc., San Diego, CA, USA.
Yacyshyn
B R
BR
Shanahan
W R
WR
Dean
N M
NM
D002986:Clinical Trials as Topic; D015195:Drug Design; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D007239:Infections / Q000188:drug therapy; D007249:Inflammation / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D016376:Oligonucleotides, Antisense / Q000494:pharmacology* / Q000627:therapeutic use*
D016376:Oligonucleotides, Antisense